Using bevacizumab to treat metastatic cancer: UK consensus guidelines Journal Articles

abstract

• Concise guidance is lacking for the use of bevacizumab by practicing oncologists. Eight oncologists with experience of bevacizumab were joined by a cardiologist interested in treating hypertension to develop practical guidelines for managing patients receiving bevacizumab, using available clinical data.

authors

• Miles, D
• Bridgewater, J
• Ellis, Peter
• Harrison, M
• Nathan, P
• Nicolson, M
• Raouf, S
• Wheatley, D
• Plummer, C

status

• published 

publication date

• December 2010

has subject area

• 1103 Clinical Sciences (FoR)
• Antibodies, Monoclonal (MeSH)
• Antibodies, Monoclonal, Humanized (MeSH)
• Antineoplastic Agents (MeSH)
• Bevacizumab (MeSH)
• Gastrointestinal Diseases (MeSH)
• General & Internal Medicine (Science Metrix)
• Hemorrhage (MeSH)
• Humans (MeSH)
• Hypertension (MeSH)
• Neoplasms (MeSH)
• Proteinuria (MeSH)
• Randomized Controlled Trials as Topic (MeSH)
• Thromboembolism (MeSH)
• Vascular Endothelial Growth Factor A (MeSH)
• Wound Healing (MeSH)

published in

• British journal of hospital medicine (London, England : 2005)  Journal

keywords

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Bevacizumab
• Gastrointestinal Diseases
• Hemorrhage
• Humans
• Hypertension
• Neoplasms
• Proteinuria
• Randomized Controlled Trials as Topic
• Thromboembolism
• Vascular Endothelial Growth Factor A
• Wound Healing

Digital Object Identifier (DOI)

• 10.12968/hmed.2010.71.12.670

PubMed ID

• 21135762

start page

• 670

end page

• 678

volume

• 71

issue

• 12